Finoriq research workspace
Avalyn Pharma Inc. (AVLN) Historical Metrics
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled. Review AVLN fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
- Company
- Avalyn Pharma Inc. (AVLN)
- Ticker
- AVLN
- Market Cap
- $1.3B
- Latest Price
- $28.61
- Industry
- Biotech & Pharma
Avalyn Pharma Inc. (AVLN) Current Valuation Metrics
Static valuation preview for Avalyn Pharma Inc. (AVLN). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Cash / Market CapCash and cash equivalents divided by market cap. | 7.1% | Cash & Cash Equivalents | Q1 2026 |
| Debt / Market CapTotal debt divided by market cap. | 1.1% | Total Debt | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.